$HUMA

Humacyte (Nasdaq: HUMA) reported Q2 2026 results and updated its pipeline. In its V012 Phase 3 dialysis access trial, ATEV outperformed AV fistula in an interim analysis of 80 female patients, with fewer catheter days and infections. Humacyte plans an sBLA filing in 2H 2026. FDA accepted an IND for CTEV in CABG; Phase 2a expected to start Q3 2026. Symvess sales were $0.4M in Q2 2026 vs $0.1M in Q2 2025.

Humacyte, Inc. (HUMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622949d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update – Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic

U.S. stock index futures edged higher ahead of July CPI at 8:30 a.m. ET. Economists expect +0.2% m/m and 3.4% y/y. Nasdaq futures were up 0.4% and S&P 500 up 0.1% by 4:00 a.m. ET. Pre-market movers included CRWV (+15%), NBIS (+8%), SMCI (+9%), and ORCL (+1%).

Humacyte, Inc. (HUMA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2617224d2_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 47,619,048 Shares HUMACYTE, INC. Common Stock UNDERWRITING AGREEMENT June 10, 2026 Barclays Capital Inc. BTIG, LLC Titan Partners Group LLC, a division of American Capital Partners, LLC As Representatives of the several Under

Humacyte (Nasdaq: HUMA) priced an underwritten public offering of 47,619,048 shares at $1.05 per share, raising about $50 million in gross proceeds, before underwriting discounts and expenses. Closing is expected around June 12, 2026. The underwriters received an option to buy up to 7,142,857 additional shares. Humacyte said net proceeds will fund Symvess commercialization, a hemodialysis BLA supplement, pipeline development, and working capital.

Humacyte, Inc. (HUMA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false --12-31 0001818382 0001818382 2026-06-09 2026-06-09 0001818382 us-gaap:CommonStockMember 2026-06-09 2026-06-09 0001818382 HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD

Humacyte (NASDAQ:HUMAW) reported a May short-interest decline, with 2,664 shares short as of May 15, down 45.1% from 4,855 shares on April 30. The short-interest ratio is 0.2 days based on average volume of 16,063 shares. The stock traded around $0.05 mid-day, with 52-week range $0.04–$0.60.

The article discusses why BTIG lowered its price target on Humacyte (HUMA) but maintained a bullish outlook due to significant long-term potential. The report likely details the reasons for the target adjustment, such as short-term challenges or market conditions, while emphasizing the company's underlying value and future growth prospects.

Humacyte (HUMA) is trading pre-market at USD 0.8541 on NASDAQ, ahead of its Q4 2025 earnings release on March 27, 2026. This earnings report is a significant catalyst due to the company's negative EPS, recent high trading volume, and its early commercialization stage. Investors will be focused on clinical trial updates, cash runway details, and any commercial milestones as these could lead to substantial intraday volatility and reset the stock's valuation.

Humacyte Inc. (HUMA) shares surged nearly 12% on Monday following the announcement that the FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels. This funding is specifically for evaluating and incorporating biologic vascular repair technologies for warfighters with traumatic vascular injuries. Humacyte's product, Symvess, is noted as the only human-derived bioengineered blood vessel approved by the FDA.